Literature DB >> 9083161

Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas.

S W Coons1, P C Johnson, B W Scheithauer, A J Yates, D K Pearl.   

Abstract

BACKGROUND: Accurate histologic diagnosis of gliomas is fundamental to proper patient management and to the interpretation of basic and clinical investigations. Diagnostic accuracy and reproducibility are compromised by the subjective histologic criteria currently used to classify and grade gliomas.
METHODS: The histologic features of 4 sets of gliomas (a total of 244 cases) were reviewed independently by 4 neuropathologists to determine interobserver diagnostic concordance rates. Cases wherein diagnostic disagreements arose were reviewed jointly to identify and refine the histologic criteria that were adversely affecting diagnostic reproducibility. Using the criteria developed in the study, a set of 315 gliomas with known survival data was evaluated in order to validate the usefulness of the criteria.
RESULTS: There was significant improvement in diagnostic concordance with each session (P = 0.02). For the first session, the concordance rates were as follows: all 4 reviewers, 52%; any 3 reviewers, 60%; 2 reviewers, 70%. For the fourth session, the respective rates were 69%, 75%, and 80%. Although features important in grading, particularly microvascular proliferation, were sometimes problematic, most disagreements related to the classification of tumors. Much of the improvement related to the refinement of criteria distinguishing diffuse astrocytomas from oligodendrogliomas/oligoastrocytomas and pilocytic astrocytomas. It was concluded that the presence of any typical oligodendroglioma was sufficient to remove a tumor from the astrocytoma category.
CONCLUSIONS: The authors' data indicate that oligodendroglial tumors comprise up to 25% of gliomas, a significantly higher proportion than was previously recognized. The data also suggest that the wide range of survival times reported for patients with anaplastic astrocytoma may reflect "contamination" resulting from misdiagnosis, particularly of oligodendroglial tumors and pilocytic astrocytomas.

Entities:  

Mesh:

Year:  1997        PMID: 9083161     DOI: 10.1002/(sici)1097-0142(19970401)79:7<1381::aid-cncr16>3.0.co;2-w

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  166 in total

Review 1.  Glioma classification: a molecular reappraisal.

Authors:  D N Louis; E C Holland; J G Cairncross
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

2.  Lhx3 is required to maintain cancer cell development of high-grade oligodendroglioma.

Authors:  Hongliang Liu; Wei Liu; Bin Zhu; Qiang Xu; Xiaowei Ni; Ji Yu
Journal:  Mol Cell Biochem       Date:  2014-11-16       Impact factor: 3.396

3.  Independent prognostic value of pre-treatment 18-FDG-PET in high-grade gliomas.

Authors:  Cécile Colavolpe; Philippe Metellus; Julien Mancini; Maryline Barrie; Céline Béquet-Boucard; Dominique Figarella-Branger; Olivier Mundler; Olivier Chinot; Eric Guedj
Journal:  J Neurooncol       Date:  2011-12-15       Impact factor: 4.130

Review 4.  Studying a complex tumor: potential and pitfalls.

Authors:  Siyuan Zheng; Milan G Chheda; Roel G W Verhaak
Journal:  Cancer J       Date:  2012 Jan-Feb       Impact factor: 3.360

5.  Imaging parameters of high grade gliomas in relation to the MGMT promoter methylation status: the CT, diffusion tensor imaging, and perfusion MR imaging.

Authors:  Won-Jin Moon; Jin Woo Choi; Hong Gee Roh; So Dug Lim; Young-Cho Koh
Journal:  Neuroradiology       Date:  2011-08-11       Impact factor: 2.804

6.  Oligodendrogliomas: a short history of clinical developments.

Authors:  Martin J van den Bent
Journal:  CNS Oncol       Date:  2015

7.  Diagnostic discrepancies in malignant astrocytoma due to limited small pathological tumor sample can be overcome by IDH1 testing.

Authors:  Betty Y S Kim; Wen Jiang; Jason Beiko; Sujit S Prabhu; Franco DeMonte; Mark R Gilbert; Raymond Sawaya; Kenneth D Aldape; Daniel P Cahill; Ian E McCutcheon
Journal:  J Neurooncol       Date:  2014-04-29       Impact factor: 4.130

8.  Patterns of care and treatment outcomes in older adults with low grade glioma: a 50-year experience.

Authors:  Ryan S Youland; David A Schomas; Paul D Brown; Ian F Parney; Nadia N I Laack
Journal:  J Neurooncol       Date:  2017-04-21       Impact factor: 4.130

9.  A glioma classification scheme based on coexpression modules of EGFR and PDGFRA.

Authors:  Yingyu Sun; Wei Zhang; Dongfeng Chen; Yuhong Lv; Junxiong Zheng; Henrik Lilljebjörn; Liang Ran; Zhaoshi Bao; Charlotte Soneson; Hans Olov Sjögren; Leif G Salford; Jianguang Ji; Pim J French; Thoas Fioretos; Tao Jiang; Xiaolong Fan
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-18       Impact factor: 11.205

10.  Gene expression profiling in glioblastoma and immunohistochemical evaluation of IGFBP-2 and CDC20.

Authors:  Gianluca Marucci; Luca Morandi; Elisabetta Magrini; Anna Farnedi; Enrico Franceschi; Rossella Miglio; Daniela Calò; Annalisa Pession; Maria P Foschini; Vincenzo Eusebi
Journal:  Virchows Arch       Date:  2008-10-25       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.